Mutares Makes Landmark $450 Million Acquisition to Enter Chemicals Sector

Mutares makes its largest-ever acquisition, buying SABIC's engineering plastics division for $450M. The deal adds $2.5B in revenue and creates a new 'Chemicals & Materials' segment.

Munich-based investment firm Mutares has announced its largest-ever acquisition, agreeing to purchase the engineering thermoplastics division of SABIC for an enterprise value of $450 million. This strategic move marks a significant diversification for the company, historically known as a turnaround specialist in the automotive, industrial, and logistics sectors. The transaction introduces an entirely new operating segment—"Chemicals & Materials"—to its portfolio.

Strategic Shift and Portfolio Expansion

The acquired business is a major global operator, not a niche player. It ranks among the world's largest producers of polycarbonate, holds a leading position in the US market for ABS resins, and is the sole domestic producer of PBT in the United States. The division's portfolio includes well-known brands such as LEXAN™ and VALOX™. The deal includes eight production sites and a workforce of approximately 2,900 employees.

Financially, the addition is substantial, bringing in annual revenues of around $2.5 billion. This will dramatically alter Mutares's geographic revenue mix, shifting its portfolio focus toward the United States, a long-stated corporate objective. Currently, 66% of the division's sales are generated in the Americas, with 34% coming from Europe. The company plans to open a second US location within the next twelve months.

Building on a Foundation of Record Performance

This ambitious acquisition follows a period of strong financial performance for Mutares. In its last fiscal year, consolidated group revenues increased from €5.3 billion to €6.5 billion. The holding company's net income rose to €130.4 million, bolstered in part by the complete exit from its investment in Steyr Motors.

Bolstered by these results and the pending acquisition, Mutares's management board has raised its medium-term targets significantly. By 2026, the company is now targeting consolidated revenues between €7.9 billion and €9.1 billion, with holding net income expected to reach €165 million to €200 million. The firm aims for both metrics to grow at an annual rate of 25% through 2030.

Regulatory Hurdles and Market Valuation

The transaction's completion remains subject to regulatory approvals, including antitrust and foreign investment clearances. The deal is anticipated to close in the second half of 2026.

Despite the operational strength demonstrated by the recent financials and the strategic rationale behind the SABIC purchase, Mutares's share price has yet to reflect this ambition. Currently trading at around €27.85, the stock sits approximately 25% below its 52-week high from March 2025. Market observers suggest that a smooth regulatory approval process, followed by initial positive contributions from the new chemicals segment, could help narrow the current valuation gap relative to analyst price targets.